U.S. Biologics Patents Could Be Designed To Benefit Developing Worlds
This article was originally published in PharmAsia News
Executive Summary
Treatments for diseases that afflict the developing world could benefit if the U.S. Congress makes the right moves in how generic versions of biotechnology drugs are regulated, according to a consultant to follow-on biologics companies. Ian Spatz of the Rock Creek Policy Group, writing in the journal Health Affairs, said that in setting the number of years of patent protection for biotech drugs or devices, Congress could provide an extension for companies that show their products are particularly suitable for use in the developing world. In some cases, the drugs or diagnostics could be for treating diseases such as HIV, taking into account the lack of proper storage capability in some developing countries. (Click here for more